Idiopathic pulmonary fibrosis (IPF) is a progressive and generally fatal disease characterized by scarring of the lungs that thickens the lining of the lungs, causing an irreversible loss of the tissue’s ability to transport oxygen. IPF ultimately robs a patient of the ability to breathe.
Research has suggested improved clinical outcomes in IPF patients treated with co-trimoxazole (Bactrim) or doxycycline .
Co-trimoxazole is used to treat certain bacterial infections, such as pneumonia (a lung infection), bronchitis (infection of the tubes leading to the lungs), and infections of the urinary tract, ears, and intestines. Co-trimoxazole is a combination of trimethoprim and sulfamethoxazole and is in a class of medications called sulfonamides. It works by stopping the growth of bacteria.
Doxycycline is used to treat bacterial infections, including pneumonia and other respiratory tract infections; Lyme disease; acne; infections of skin, genital, urinary systems; and to prevent malaria. Doxycycline is in a class of medications called tetracycline antibiotics. It works by preventing the growth and spread of bacteria.
Our trial hopes to show that antimicrobial therapy in addition to standard clinical care compared to standard clinical care alone in IPF patients will improve clinical outcomes such as the length of time to a rehospitalization. Participants will be randomized to maintain their current care or to add Co-trimoxazole or Doxycycline.
Participants may be in the trial for up to 42 months. There are face to face visits at the clinic every 12 months for two years, and contact by phone every 6 months. Participants will be compensated for their time and expense.